日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Evaluation of the effectiveness and safety of ONO-2910 for the treatment of diabetic polyneuropathy: An early Phase IIa, multicenter, randomized, placebo-controlled, double-blind study in Japanese patients

评估 ONO-2910 治疗糖尿病性多发性神经病的有效性和安全性:一项在日本患者中进行的早期 IIa 期多中心随机、安慰剂对照、双盲研究

Onishi, Yukiko; Osonoi, Takeshi; Takahashi, Norio; Takiguchi, Toru; Morishima, Eiichiro; Aso, Yoshimasa; Sekiguchi, Kenji; Kamiya, Hideki; Nakamura, Jiro

Modeling Transmembrane 6 Superfamily Member 2 p.Glu167Lys-associated Steatotic Liver Disease Using Androgen-treated Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells

利用雄激素处理的人类诱导多能干细胞衍生的肝细胞样细胞模拟跨膜6超家族成员2 p.Glu167Lys相关脂肪肝疾病

Hirai, Asei; Yoneyama, Yosuke; Assi, Ismael; Osonoi, Sho; Sakai, Sosuke; Ohtsu, Kanae; Takebe, Takanori

Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial

在日本2型糖尿病患者中,伊美格列明联合DPP-4抑制剂治疗的疗效和安全性:一项随机、双盲FAMILIAR试验的中期分析

Kaku, Kohei; Shimoda, Masashi; Osonoi, Takeshi; Iwamoto, Masahiro; Kaneto, Hideaki

Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study

从非布司他换用新型选择性尿酸重吸收抑制剂多替努拉,可通过抑制 URAT1 显著降低血清尿酸水平,且可能不会对 ABCG2 功能产生不利影响:SWITCH SURI 研究结果

Osonoi, Takeshi; Shirabe, Shinichiro; Saito, Miyoko; Hosoya, Mitsuru; Watahiki, Norie; Douguchi, Satako; Ofuchi, Kensuke; Katoh, Makoto

Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial

伊美格列明可能通过延长2型糖尿病患者红细胞寿命来影响糖化血红蛋白A1c的准确性:来自INFINITY临床试验的启示

Osonoi, Takeshi; Shirabe, Shinichiro; Saito, Miyoko; Hosoya, Mitsuru; Watahiki, Norie; Shiozawa, Nana; Douguchi, Satako; Ofuchi, Kensuke; Katoh, Makoto

Hypertension is associated with the reduction in epidermal small fibres independently of sural nerve inflammation in type 2 diabetic subjects

高血压与 2 型糖尿病患者表皮小纤维的减少有关,与腓肠神经炎症无关

Zhenchao Wang, Hanae Kushibiki, Takefusa Tarusawa, Sho Osonoi, Saori Ogasawara, Chinatsu Miura, Takanori Sasaki, Masaki Ryuzaki, Soroku Yagihashi, Hiroki Mizukami

Long-term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52-week postmarketing clinical study (TWINKLE)

伊美格列明在日本2型糖尿病合并慢性肾病患者中的长期安全性和有效性:一项为期52周的上市后临床研究(TWINKLE)

Babazono, Tetsuya; Osonoi, Takeshi; Okamoto, Hideki; Onishi, Yukiko; Nakamoto, Shinya; Kashima, Masayuki; Kawanami, Daiji; Nakashima, Eitaro; Watabe, Kei; Nunami, Noriko; Hagi, Katsuhiko

Upgrade of the KWS-2 high-intensity/extended-Q-range SANS diffractometer of JCNS for soft matter and biophysics: in situ SEC, controlled in situ RH/T variation and WANS detection.

JCNS KWS-2 高强度/扩展 Q 范围 SANS 衍射仪的升级,用于软物质和生物物理:原位 SEC、受控原位 RH/T 变化和 WANS 检测

Kang Jia-Jhen, Biehl Ralf, Brandl Georg, Korb Helmut, Yoshimura Kimio, Ossovyi Vladimir, Nebel Andreas, Lippertz Jacqueline, Engels Ralf, Kemmerling Günter, Zaft Alexander, Iwase Hiroki, Arima-Osonoi Hiroshi, Takata Shin-Ichi, Weber Alexander, Staringer Simon, Wu Baohu, Zhao Yue, Mattauch Stefan, Radulescu Aurel

Long-term efficacy and safety of early sitagliptin initiation in individuals with type 2 diabetes: an extension of the SPIKE study

西格列汀早期应用于2型糖尿病患者的长期疗效和安全性:SPIKE研究的扩展研究

Mita, Tomoya; Katakami, Naoto; Yoshii, Hidenori; Onuma, Tomio; Kaneto, Hideaki; Osonoi, Takeshi; Shiraiwa, Toshihiko; Yasuda, Tetsuyuki; Umayahara, Yutaka; Yamamoto, Tsunehiko; Yokoyama, Hiroki; Kuribayashi, Nobuichi; Matsumoto, Kazunari; Gosho, Masahiko; Shimomura, Iichiro; Watada, Hirotaka

Organoid-guided precision hepatology for metabolic liver disease

类器官引导的精准肝病学在代谢性肝病治疗中的应用

Osonoi, Sho; Takebe, Takanori